FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.

被引：1
|
作者：
Murphy, Janet E.
Wo, Jennifer Yon-Li
Ryan, David P.
Jiang, Wenqing
Yeap, Beow Y.
Blaszkowsky, Lawrence Scott
Kwak, Eunice Lee
Allen, Jill N.
Clark, Jeffrey W.
Faris, Jason Edward
Zhu, Andrew X.
Goyal, Lipika
Mamon, Harvey J.
Lillemoe, Keith D.
DeLaney, Thomas F.
Castillo, Carlos Fernandez-del
Ferrone, Cristina
Hong, Theodore S.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[6] NSABP NRG Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.368
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
368
引用
收藏
页数：1
相关论文
共 3 条
  • [1] FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, RO resection, and interim survival data from a prospective phase II study.
    Murphy, Janet E.
    Wo, Jennifer Yon-Li
    Ryan, David P.
    Jiang, Wenqing
    Yeap, Beow Y.
    Drapek, Lorraine C.
    Blaszkowsky, Lawrence Scott
    Kwak, Eunice Lee
    Allen, Jill N.
    Clark, Jeffrey W.
    Faris, Jason Edward
    Zhu, Andrew X.
    Goyal, Lipika
    Mamon, Harvey J.
    Wolpin, Brian M.
    Lillemoe, Keith D.
    DeLaney, Thomas F.
    Fernandez-del Castillo, Carlos
    Ferrone, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study
    Murphy, Janet E.
    Wo, Jennifer Yon-Li
    Ferrone, Cristina
    Jiang, Wenqing
    Yeap, Beow Y.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.
    Murphy, Janet E.
    Wo, Jennifer Yon-Li
    Ryan, David P.
    Jiang, Wenqing
    Yeap, Beow Y.
    Duda, Gabriel Dan
    Allen, Jill N.
    Blaszkowsky, Lawrence Scott
    Ferrone, Cristina
    Parikh, Aparna Raj
    Nipp, Ryan David
    Zhu, Andrew X.
    Goyal, Lipika
    Lillemoe, Keith D.
    DeLaney, Thomas F.
    Jain, Rakesh K.
    Clark, Jeffrey W.
    Boucher, Yves
    Fernandez-del Castillo, Carlos
    Hong, Theodore S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
1